Vasoactive intestinal peptide acts via multiple signal pathways to regulate hippocampal NMDA receptors and synaptic transmission

Hippocampus

Volumn 19, Issue 9, 2009, Pages 779-789

  Yang, Kai ^a   Trepanier, Catherine H ^b   Li, Hongbin ^a   Beazely, Michael A ^c   Lerner, Ethan A ^d   Jackson, Michael F ^e   MacDonald, John F ^e  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITY OF WATERLOO   (Canada)

^d MASSACHUSETTS GENERAL HOSPITAL   (United States)

^e ROBARTS RESEARCH INSTITUTE   (Canada)

Author keywords

AKAP; cAMP PKA; NMDA receptor; VIP; VPAC receptor

Indexed keywords

BISINDOLYLMALEIMIDE; CYCLIC AMP; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE; HYPOPHYSIS ADENYLATE CYCLASE ACTIVATING POLYPEPTIDE RECEPTOR 1; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; PHOSPHODIESTERASE IV; SCAFFOLD PROTEIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME INHIBITION; HIPPOCAMPUS; LEARNING; MALE; MEMORY; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; RAT; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION;

ADENYLATE CYCLASE; ANIMALS; CELL MEMBRANE; CELLS, CULTURED; CYCLIC AMP; HIPPOCAMPUS; MALE; MEMBRANE POTENTIALS; NEURONS; PATCH-CLAMP TECHNIQUES; RATS; RATS, WISTAR; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, VASOACTIVE INTESTINAL PEPTIDE; SIGNAL TRANSDUCTION; SYNAPTIC TRANSMISSION; THIONUCLEOTIDES; TIME FACTORS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 69249085343     PISSN: 10509631     EISSN: 10981063     Source Type: Journal    
DOI: 10.1002/hipo.20559     Document Type: Article

References (50)

1. Abraham WC. 2008. Metaplasticity: Tuning synapses and networks for plasticity. Nat Rev Neurosci 9:387.
2. Abraham WC, Bear MF. 1996. Metaplasticity: The plasticity of synaptic plasticity. Trends Neurosci 19:126-130.
3. Ahmed T, Frey JU. 2003. Expression of the specific type IV phosphodiesterase gene PDE4B3 during different phases of long-term potentiation in single hippocampal slices of rats in vitro. Neuroscience 117:627-638.
4. Bourtchouladze R, Lidge R, Catapano R, Stanley J, Gossweiler S, Romashko D, Scott R, Tully T. 2003. A mouse model of Rubinstein-Taybi syndrome: Defective long-term memory is ameliorated by inhibitors of phosphodiesterase 4. Proc Natl Acad Sci USA 100:10518-10522.
5. Card GL, Blasdel L, England BP, Zhang C, Suzuki Y, Gillette S, Fong D, Ibrahim PN, Artis DR, Bollag G, Milburn MV, Kim SH, Schlessinger J, Zhang KY. 2005. A family of phosphodiesterase inhibitors discovered by cocrystallography and scaffold-based drug design. Nat Biotechnol 23:201-207.
6. Chen WS, Bear MF. 2007. Activity-dependent regulation of NR2B translation contributes to metaplasticity in mouse visual cortex. Neuropharmacology 52:200-214.
7. Ciranna L, Cavallaro S. 2003. Opposing effects by pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal peptide on hippocampal synaptic transmission. Exp Neurol 184:778-784.
8. Citri A, Malenka RC. 2008. Synaptic plasticity: Multiple forms, functions, and mechanisms. Neuropsychopharmacology 33:18-41.
9. Claing A, Perry SJ, Achiriloaie M, Walker JK, Albanesi JP, Lefkowitz RJ, Premont RT. 2000. Multiple endocytic pathways of G protein-coupled receptors delineated by GIT1 sensitivity. Proc Natl Acad Sci USA 97:1119-1124.
10. Crump FT, Dillman KS, Craig AM. 2001. cAMP-dependent protein kinase mediates activity-regulated synaptic targeting of NMDA receptors. J Neurosci 21:5079-5088.
11. Cunha-Reis D, Fontinha BM, Ribeiro JA, Sebastiao AM. 2007. Tonic adenosine A1 and A2A receptor activation is required for the excitatory action of VIP on synaptic transmission in the CA1 area of the hippocampus. Neuropharmacology 52:313-320.
12. Cunha-Reis D, Ribeiro JA, Sebastiao AM. 2005. VIP enhances synaptic transmission to hippocampal CA1 pyramidal cells through activation of both VPAC1 and VPAC2 receptors. Brain Res 1049:52-60.
13. Cunha-Reis D, Ribeiro JA, Sebastiao AM. 2006. VPAC2 receptor activation mediates VIP enhancement of population spikes in the CA1 area of the hippocampus. Ann NY Acad Sci 1070:210-214.
14. Cunha-Reis D, Sebastiao AM, Wirkner K, Illes P, Ribeiro JA. 2004. VIP enhances both pre- and postsynaptic GABAergic transmission to hippocampal interneurones leading to increased excitatory synaptic transmission to CA1 pyramidal cells. Br J Pharmacol 143:733-744.
15. Dejda A, Sokolowska P, Nowak JZ. 2005. Neuroprotective potential of three neuropeptides PACAP, VIP and PHI. Pharmacol Rep 57:307-320.
16. Dickinson T, Fleetwood-Walker SM, Mitchell R, Lutz EM. 1997. Evidence for roles of vasoactive intestinal polypeptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) receptors in modulating the responses of rat dorsal horn neurons to sensory inputs. Neuropeptides 31:175-185.
17. Gaudin P, Couvineau A, Maoret JJ, Rouyer-Fessard C, Laburthe M. 1996. Stable expression of the recombinant human VIP1 receptor in clonal Chinese hamster ovary cells: Pharmacological, functional and molecular properties. Eur J Pharmacol 302:207-214.
18. Ghavami A, Hirst WD, Novak TJ. 2006. Selective phosphodiesterase (PDE)-4 inhibitors: A novel approach to treating memory deficit? Drugs RD 7:63-71.
19. Goursaud S, Maloteaux JM, Hermans E. 2008. Activation of VIP/PACAP type 2 receptor by the peptide histidine isoleucine in astrocytes influences GLAST-mediated glutamate uptake. J Neurochem 105:1165-1175.
20. Gozes I, Bachar M, Bardea A, Davidson A, Rubinraut S, Fridkin M, Giladi E. 1997. Protection against developmental retardation in apolipoprotein E-deficient mice by a fatty neuropeptide: Implications for early treatment of Alzheimer's disease. J Neurobiol 33:329-342.
21. Hagen BM, Bayguinov O, Sanders KM. 2006. VIP and PACAP regulate localized Ca2+ transients via cAMP-dependent mechanism. Am J Physiol Cell Physiol 291:C375-C385.
22. Harmar AJ, Arimura A, Gozes I, Journot L, Laburthe M, Pisegna JR, Rawlings SR, Robberecht P, Said SI, Sreedharan SP, Wank SA, Waschek JA. 1998. International Union of Pharmacology. XVIII. Nomenclature of receptors for vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. Pharmacol Rev 50:265-270.
23. Huang Y, Lu W, Ali DW, Pelkey KA, Pitcher GM, Lu YM, Aoto H, Roder JC, Sasaki T, Salter MW, MacDonald JF. 2001. CAKbeta/Pyk2 kinase is a signaling link for induction of long-term potentiation in CA1 hippocampus. Neuron 29:485-496.
24. Joo KM, Chung YH, Kim MK, Nam RH, Lee BL, Lee KH, Cha CI. 2004. Distribution of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide receptors (VPAC1, VPAC2, and PAC1 receptor) in the rat brain. J Comp Neurol 476:388-413.
25. Kotecha SA, Jackson MF, Al Mahrouki A, Roder JC, Orser BA, MacDonald JF. 2003. Co-stimulation of mGluR5 and N-methyl-D-aspartate receptors is required for potentiation of excitatory synaptic transmission in hippocampal neurons. J Biol Chem 278:27742-27749.
26. Lu WY, Xiong ZG, Lei S, Orser BA, Dudek E, Browning MD, MacDonald JF. 1999. G-protein-coupled receptors act via protein kinase C, Src to regulate NMDA receptors. NatNeurosci 2:331-338.
27. Luo X, Zeng W, Xu X, Popov S, Davignon I, Wilkie TM, Mumby SM, Muallem S. 1999. Alternate coupling of receptors to Gs and Gi in pancreatic and submandibular gland cells. J Biol Chem 274:17684-17690.
28. Macdonald DS, Weerapura M, Beazely MA, Martin L, Czerwinski W, Roder JC, Orser BA, MacDonald JF. 2005. Modulation of NMDA receptors by pituitary adenylate cyclase activating peptide in CA1 neurons requires G alpha q, protein kinase C, activation of Src. J Neurosci 25:11374-11384.
29. Malenka RC, Bear MF. 2004. LTP and LTD: An embarrassment of riches. Neuron 44:5-21.
30. McCulloch DA, MacKenzie CJ, Johnson MS, Robertson DN, Holland PJ, Ronaldson E, Lutz EM, Mitchell R. 2002. Additional signals from VPAC/PAC family receptors. Biochem Soc Trans 30:441-446.
31. McDonald TP, Dinnis DM, Morrison CF, Harmar AJ. 1998. Desensitization of the human vasoactive intestinal peptide receptor (hVIP2/PACAP R): Evidence for agonist-induced receptor phosphorylation and internalization. Ann NY Acad Sci 865:64-72.
32. Moro O, Lerner EA. 1997. Maxadilan, the vasodilator from sand flies, is a specific pituitary adenylate cyclase activating peptide type I receptor agonist. J Biol Chem 272:966-970.
33. Moro O, Wakita K, Ohnuma M, Denda S, Lerner EA, Tajima M. 1999. Functional characterization of structural alterations in the sequence of the vasodilatory peptide maxadilan yields a pituitary adenylate cyclase-activating peptide type 1 receptor-specific antagonist. J Biol Chem 274:23103-23110.
34. Nicole P, Rouyer-Fessard C, Couvineau A, Drouot C, Fulcrand P, Martinez J, Laburthe M. 2000. Alanine scanning of VIP. Structure-function relationship for binding to human recombinant VPAC1 receptor. Ann NY Acad Sci 921:352-356.
35. Papadia S, Hardingham GE. 2007. The dichotomy of NMDA receptor signaling. Neuroscientist 13:572-579.
36. Raman IM, Tong G, Jahr CE. 1996. Beta-adrenergic regulation of synaptic NMDA receptors by cAMP-dependent protein kinase. Neuron 16:415-421.
37. Rangon CM, Goursaud S, Medja F, Lelievre V, Mounien L, Husson I, Brabet P, Jegou S, Janet T, Gressens P. 2005. VPAC2 receptors mediate vasoactive intestinal peptide-induced neuroprotection against neonatal excitotoxic brain lesions in mice. J Pharmacol Exp Ther 314:745-752.
38. Said SI, Dickman K, Dey RD, Bandyopadhyay A, De Stefanis P, Raza S, Pakbaz H, Berisha HI. 1998. Glutamate toxicity in the lung and neuronal cells: Prevention or attenuation by VIP, PACAP. Ann NY Acad Sci 865:226-237.
39. Said SI, Mutt V. 1970. Polypeptide with broad biological activity: Isolation from small intestine. Science 169:1217-1218.
40. Skeberdis VA, Chevaleyre V, Lau CG, Goldberg JH, Pettit DL, Suadicani SO, Lin Y, Bennett MV, Yuste R, Castillo PE, Zukin RS. 2006. Protein kinase A regulates calcium permeability of NMDA receptors. Nat Neurosci 9:501-510.
41. Snyder EM, Colledge M, Crozier RA, Chen WS, Scott JD, Bear MF. 2005. Role for A kinase-anchoring proteins (AKAPS) in glutamate receptor trafficking and long term synaptic depression. J Biol Chem 280:16962-16968.
42. Svenningsson P, Nishi A, Fisone G, Girault JA, Nairn AC, Greengard P. 2004. DARPP-32: An integrator of neurotransmission. Annu Rev Pharmacol Toxicol 44:269-296.
43. Tasken K, Aandahl EM. 2004. Localized effects of cAMP mediated by distinct routes of protein kinase A. Physiol Rev 84:137-167.
44. Tsutsumi M, Claus TH, Liang Y, Li Y, Yang L, Zhu J, Dela CF, Peng X, Chen H, Yung SL, Hamren S, Livingston JN, Pan CQ. 2002. A potent and highly selective VPAC2 agonist enhances glucose-induced insulin release and glucose disposal: A potential therapy for type 2 diabetes. Diabetes 51:1453-1460.
45. Vaudry D, Gonzalez BJ, Basille M, Yon L, Fournier A, Vaudry H. 2000. Pituitary adenylate cyclase-activating polypeptide and its receptors: From structure to functions. Pharmacol Rev 52:269-324.
46. Vijayaraghavan S, Goueli SA, Davey MP, Carr DW. 1997. Protein kinase A-anchoring inhibitor peptides arrest mammalian sperm motility. J Biol Chem 272:4747-4752.
47. Waelbroeck M, Robberecht P, Coy DH, Camus JC, De Neef P, Christophe J. 1985. Interaction of growth hormone-releasing factor (GRF) and 14 GRF analogs with vasoactive intestinal peptide (VIP) receptors of rat pancreas. Discovery of (N-Ac-Tyr1,D-Phe2)-GRF(1-29)-NH2 as a VIP antagonist. Endocrinology 116:2643-2649.
48. Wang LY, MacDonald JF. 1995. Modulation by magnesium of the affinity of NMDA receptors for glycine in murine hippocampal neurones. J Physiol 486 (Part 1):83-95.
49. Westphal RS, Tavalin SJ, Lin JW, Alto NM, Fraser ID, Langeberg LK, Sheng M, Scott JD. 1999. Regulation of NMDA receptors by an associated phosphatase-kinase signaling complex. Science 285:93-96.
50. Yaka R, He DY, Phamluong K, Ron D. 2003. Pituitary adenylate cyclase-activating polypeptide (PACAP (1-38)) enhances N-methyl-D-aspartate receptor function and brain-derived neurotrophic factor expression via RACK1. J Biol Chem 278:9630-9638.